Goldman Sachs Downgrades Myriad Genetics (MYGN) to Neutral Following SCOTUS Case

Article Related Press Releases (1) Related Articles (6) Stock Quotes (1) Comments (0)

Goldman Sachs downgraded Myriad Genetics (NASDAQ: MYGN) from Buy to Neutral with a price target of $26.00 (from $34.00) after the Supreme Court of the United States (SCOTUS) agreed to hear the case against the company relating to the patentability of genes.

Given this overhang, Goldman said their buy thesis is now impaired.

For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.

Shares of Myriad Genetics closed at $28.72 yesterday, with a 52 week range of $19.21-$31.80.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
• RBC Capital Downgrades MeadWestvaco (MWV) to Underperform
• Atlantic Equities Downgrades Walt Disney (DIS) to Neutral

Create E-mail Alert Related Categories

Analyst PT Change, Downgrades

Related Entities

Goldman Sachs

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?